This page shows the latest darolutamide news and features for those working in and with pharma, biotech and healthcare.
Bayer’s Nubeqa (darolutamide) tablets plus androgen deprivation therapy (ADT), in combination with docetaxel, have been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of metastatic
Bayer’s Nubeqa (darolutamide) tablets, in combination with docetaxel, have been approved by the US Food and Drug Administration (FDA) to treat adults with metastatic hormone-sensitive prostate cancer (mHSPC).
Bayer/Orion’s Nubeqa (darolutamide) is a more recent competitor and it has been approved for the treatment of nmCRPC in men.
The EC has approved Nubeqa (darolutamide) as a treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC), which has become an increasingly competitive therapy area. ... With the authorisation of darolutamide in the EU,
Other notable recommendations include Bayer’s Nubeqa (darolutamide), which has been recommended for approval as a treatment for prostate cancer.
So far, Erleada – which was also approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) a few months ahead of Xtandi and Bayer’s recently-approved competitor Nubeqa (darolutamide) –
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...